No Data
No Data
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Terns Stock Jumps as Weight Loss Drug Succeeds in Early Trial
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
Is Novo Nordisk A/S (NVO) A Good Biotech Stock to Buy?
Why Big Pharma Is Betting on Telehealth Strategies
MonkeyGee : if you need a pill to lose weight, you have other issues.
Learning_Piggy : I used to think this way until I looked around and see more than a few obese people never managed to get out of obesity by themselves.
With or without surgery, with or without dietary restriction, obesity will most likely come back to them and it takes more than just personal grit to fight it.
InfiltradeR Learning_Piggy : Let's not forget the ever rising diabetes numbers.
Learning_Piggy InfiltradeR : exactly!